TGen Drug Development

TGen Drug Development (TD2) is an oncology drug development organization offering preclinical, regulatory, and clinical trial services. Since its inception in 2003, TD2 has assisted over 200 pharmaceutical and biotechnology companies across the US, Europe and Asia in the preclinical and clinical development of their oncology pipeline. TD2 is located in Scottsdale, Arizona on the campus of the Mayo Clinic and is a wholly owned subsidiary of the Translational Genomics Research Institute (TGen), specialized with in vitro and in vivo studies, phase I-III clinical trials, and supportive services such as program analysis and medical writing. TD2 focuses include tumor xenograft cancer models (CRO Oncology), oncology relevant cell lines, and in vivo imaging. TD2's in vitro and in vivo preclinical studies support the clinical development plan services. TD2's regulatory services facilitate the completion and submission of regulatory applications, i.e. Investigational New Drug, Special Protocol Assessment, Orphan Drug Designation, Accelerated Approval, etc. TD2 also designs and manages Ph I - III clinical trials, offering supportive services such as program analysis, medical writing, and turnkey trial management.
TD2 manages clinical trials on behalf of pharmaceutical customers like many , and provides the following services:
* Management of clinical trials, data, projects and providing laboratory services
* Preclinical research services (AAALAC accreditation, June 2012)
* Regulatory services
Affiliated Organizations
TGen, Van Andel Institute, FORMA Therapeutics
History
: TGen Drug Development (TD2) specializes in contract research in the oncology industry. TD2 is located in Scottsdale, Arizona and is a wholly owned subsidiary of the Translational Genomics Research Institute (TGen) and is located on the campus of the Mayo Clinic. TD2 was established in 2003 and founded by Dr. Jeffrey Trent, Dr. Daniel Von Hoff, and Mr. Richard Love (Forbes).

Main Menu

See Also

Main Menu